Cargando…

Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open-label, phase 1 trial

BACKGROUND: The Middle East respiratory syndrome coronavirus (MERS-CoV) causes a respiratory disease with a case fatality rate of up to 35%. Given its potential to cause a public health emergency and the absence of efficacious drugs or vaccines, MERS is one of the WHO priority diseases warranting ur...

Descripción completa

Detalles Bibliográficos
Autores principales:	Koch, Till, Dahlke, Christine, Fathi, Anahita, Kupke, Alexandra, Krähling, Verena, Okba, Nisreen M A, Halwe, Sandro, Rohde, Cornelius, Eickmann, Markus, Volz, Asisa, Hesterkamp, Thomas, Jambrecina, Alen, Borregaard, Saskia, Ly, My L, Zinser, Madeleine E, Bartels, Etienne, Poetsch, Joseph S H, Neumann, Reza, Fux, Robert, Schmiedel, Stefan, Lohse, Ansgar W, Haagmans, Bart L, Sutter, Gerd, Becker, Stephan, Addo, Marylyn M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2020
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172913/ https://www.ncbi.nlm.nih.gov/pubmed/32325037 http://dx.doi.org/10.1016/S1473-3099(20)30248-6

Ejemplares similares

Increased neutralization and IgG epitope identification after MVA-MERS-S booster vaccination against Middle East respiratory syndrome
por: Fathi, Anahita, et al.
Publicado: (2022)

Protective CD8+ T Cell Response Induced by Modified Vaccinia Virus Ankara Delivering Ebola Virus Nucleoprotein
por: Kupke, Alexandra, et al.
Publicado: (2022)

Dose-dependent T-cell Dynamics and Cytokine Cascade Following rVSV-ZEBOV Immunization()
por: Dahlke, Christine, et al.
Publicado: (2017)

2343. SARS-CoV-2 Spike Conformation Essentially Influences Vaccine Immunogenicity – Results from Two Clinical Phase I Trials of the Vector Vaccine Candidates MVA-SARS-2-S and MVA-SARS-2-ST
por: Fathi, Anahita, et al.
Publicado: (2023)

Non-plaque-forming virions of Modified Vaccinia virus Ankara express viral genes
por: Lülf, Anna-Theresa, et al.
Publicado: (2016)

Modified Vaccinia Virus Ankara (MVA) as Production Platform for Vaccines against Influenza and Other Viral Respiratory Diseases
por: Altenburg, Arwen F., et al.
Publicado: (2014)

Tracking Modified Vaccinia Virus Ankara in the Chicken Embryo: In Vivo Tropism and Pathogenesis of Egg Infections
por: Langenmayer, Martin C., et al.
Publicado: (2018)

Detectable Vesicular Stomatitis Virus (VSV)–Specific Humoral and Cellular Immune Responses Following VSV–Ebola Virus Vaccination in Humans
por: Poetsch, Joseph H, et al.
Publicado: (2019)

E3L and F1L Gene Functions Modulate the Protective Capacity of Modified Vaccinia Virus Ankara Immunization in Murine Model of Human Smallpox
por: Volz, Asisa, et al.
Publicado: (2018)

Monkeypox Virus Cross-Neutralizing Antibodies in Clinical Trial Participants Vaccinated With Modified Vaccinia Virus Ankara Encoding Middle East Respiratory Syndrome–Coronavirus Spike Protein
por: Raadsen, Matthijs P, et al.
Publicado: (2023)

Systems Vaccinology Identifies an Early Innate Immune Signature as a Correlate of Antibody Responses to the Ebola Vaccine rVSV-ZEBOV
por: Rechtien, Anne, et al.
Publicado: (2017)

CD8+ T Cells Responding to the Middle East Respiratory Syndrome Coronavirus Nucleocapsid Protein Delivered by Vaccinia Virus MVA in Mice
por: Veit, Svenja, et al.
Publicado: (2018)

Modified Vaccinia Virus Ankara: History, Value in Basic Research, and Current Perspectives for Vaccine Development
por: Volz, A., et al.
Publicado: (2017)

Recombinant vesicular stomatitis virus vector vaccines for WHO blueprint priority pathogens
por: Fathi, Anahita, et al.
Publicado: (2019)

Sex Differences in Immunity: Implications for the Development of Novel Vaccines Against Emerging Pathogens
por: Fathi, Anahita, et al.
Publicado: (2021)

Development and characterization of an indirect ELISA to detect SARS-CoV-2 spike protein-specific antibodies
por: Krähling, Verena, et al.
Publicado: (2021)

Activation of interferon regulatory factor 3 by replication-competent vaccinia viruses improves antitumor efficacy mediated by T cell responses
por: Riederer, Stephanie, et al.
Publicado: (2021)

Direct intranodal tonsil vaccination with modified vaccinia Ankara vaccine protects macaques from highly pathogenic SIVmac251
por: Mattathil, Jeffy G., et al.
Publicado: (2023)

Distribution and absence of generalized lesions in mice following single dose intramuscular inoculation of the vaccine candidate MVA-MERS-S
por: Langenmayer, Martin C., et al.
Publicado: (2018)

Modified Vaccinia Virus Ankara Preferentially Targets Antigen Presenting Cells In Vitro, Ex Vivo and In Vivo
por: Altenburg, Arwen F., et al.
Publicado: (2017)

Persistence of MERS-CoV-spike-specific B cells and antibodies after late third immunization with the MVA-MERS-S vaccine
por: Weskamm, Leonie M., et al.
Publicado: (2022)

Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA-SARS-2-S in preclinical vaccination
por: Tscherne, Alina, et al.
Publicado: (2021)

Stabilized recombinant SARS-CoV-2 spike antigen enhances vaccine immunogenicity and protective capacity
por: Meyer zu Natrup, Christian, et al.
Publicado: (2022)

Recombinant Modified Vaccinia Virus Ankara Expressing Glycoprotein E2 of Chikungunya Virus Protects AG129 Mice against Lethal Challenge
por: van den Doel, Petra, et al.
Publicado: (2014)

Mini-laparoscopy as a diagnostic tool for abdominal tuberculosis: a retrospective series of 29 cases
por: Brehm, Thomas Theo, et al.
Publicado: (2022)

Generation of therapeutic antisera for emerging viral infections
por: Schmidt, Rebecca, et al.
Publicado: (2018)

Middle East respiratory syndrome coronavirus vaccines: current status and novel approaches
por: Okba, Nisreen MA, et al.
Publicado: (2017)

Short- and Long-Interval Prime-Boost Vaccination with the Candidate Vaccines MVA-SARS-2-ST and MVA-SARS-2-S Induces Comparable Humoral and Cell-Mediated Immunity in Mice
por: Kalodimou, Georgia, et al.
Publicado: (2023)

A vital gene for modified vaccinia virus Ankara replication in human cells
por: Sutter, Gerd
Publicado: (2020)

Ebola and Psychological Stress of Health Care Professionals
por: Lehmann, Marco, et al.
Publicado: (2015)

Flow cytometric protocol to characterize human memory B cells directed against SARS-CoV-2 spike protein antigens
por: Weskamm, Leonie M., et al.
Publicado: (2022)

MERS-coronavirus: From discovery to intervention
por: Widagdo, W., et al.
Publicado: (2016)

Viren überlisten: Globale Virusinfektionen werden beherrschbar – aber neue Gefahren drohen
por: Addo, Marylyn Martina, et al.
Publicado: (2016)

Rapid and Effective Virucidal Activity of Povidone-Iodine Products Against Middle East Respiratory Syndrome Coronavirus (MERS-CoV) and Modified Vaccinia Virus Ankara (MVA)
por: Eggers, Maren, et al.
Publicado: (2015)

Tick-Borne Encephalitis Virus: A Quest for Better Vaccines against a Virus on the Rise
por: Kubinski, Mareike, et al.
Publicado: (2020)

Obstetric Ultrasonography to Detect Fetal Abnormalities in a Mouse Model for Zika Virus Infection
por: Forster, Dominik, et al.
Publicado: (2020)

Mouse models in COVID-19 research: analyzing the adaptive immune response
por: Clever, Sabrina, et al.
Publicado: (2022)

Modified vaccinia virus Ankara as antigen delivery system: how can we best use its potential?
por: Drexler, Ingo, et al.
Publicado: (2004)

A poxvirus-based vaccine reduces virus excretion after MERS coronavirus infection in dromedary camels
por: Stalin Raj, V., et al.
Publicado: (2016)

Newly Designed Poxviral Promoters to Improve Immunogenicity and Efficacy of MVA-NP Candidate Vaccines against Lethal Influenza Virus Infection in Mice
por: Langenmayer, Martin C., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_rd45og841kvrna6sg7c91tr58t